Table 3.

Multivariate analysis

Variables	Relative Risk (95% CI)	P-value
TRM
ATG: Yes vs. No	2.13 (1.40 – 3.25)	<0.001
Donor type: Unrelated mismatched vs well matched	2.07 (1.17 – 3.84)	0.02
Relapse
Age: >60 vs. ≤60	1.93 (1.07 – 3.48)	0.028
Histology: Diffuse Large B Cell vs. Follicular	3.46 (1.80 – 6.34)	<0.001
Status: REL Resistant vs. CR2+	5.05 (2.13 – 11.99)	<0.001
Year of transplant: 2003–4 vs. 1997 -00	2.87 (1.25 – 6.58)	0.013
Risk of Treatment Failure
Histology: Lymphoblastic/Burkitts/Burkitt-like vs. Follicular	2.11 (1.40 – 3.18)	<0.001
Status: REL Resistant vs. CR2+	2.54 (1.50 – 4.31)	0.001
ATG: Yes vs. No	1.50 (1.07 – 2.10)	0.020
Time from diagnosis to transplant: 12 – 24 months vs. ≥ 24	1.58 (1.09 – 2.31)	0.017
Risk of Mortality
Age: >60 vs. ≤ 60	1.77 (1.16 – 2.70)	0.009
Time from diagnosis to transplant: 12 – 24 months vs. ≥ 24	2.26 (1.56 – 3.27)	<0.001
TBI: No vs. Yes	2.17 (1.36 – 3.48)	0.001
Donor type: Unrelated mismatched vs. well matched	2.20 (1.24 – 3.90)	0.007
GVHD prophylaxis: ex vivo T-cell depletion vs. FK506/MTX	6.0 (2.68 – 13.45)	<0.001

Abbreviations: ATG = anti-thymocyte globulin; rel = relapse; CR = complete remission; GVHD = graft vs. host disease; FK506 = tacrolimus; MTX = methotrexate.